Abstract
The COVID-19 pandemic has posed novel infection-control challenges for hospitals around the globe. One infection-control strategy that has been widely used in the context of other outbreaks is patient cohorting. This strategy refers to the placement of all patients exposed to the same laboratory-confirmed infectious agent in one location within the hospital. Little is known about the current utilization of this strategy with non-critically ill COVID-19 patients. An international multicenter, survey study was conducted to identify what strategies are planned or in place for patients with COVID-19 who are not critically ill. The survey was distributed from March 23-29th, 2020 to GIM physicians in Canada, USA, Denmark, Singapore, Hong Kong, and England. Of the 31 hospitals, 29 (94%) indicated that they plan on cohorting all GIM patients with COVID-19 to one location in the hospital. Among these 29 hospitals, 23 (79%) had implemented the plan at the time of the survey. The primary reasons for this decision were to limit the spread of COVID-19 and conserve PPE use. In conclusion, in the face of a novel virus there is near unanimity in the practice of patient cohorting as a potential mitigation strategy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sinai Health System Research Ethics Board
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos